Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tLNP CAR-T
- Development stage
- Preclinical
- Lead developer
- Taiwan Liposome Company
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
tLNP CAR-T is an investigational therapeutic program being developed by TLC BioSciences (Taiwan Liposome Company) that combines Chimeric Antigen Receptor T-cell (CAR-T) technology with a proprietary targeted lipid nanoparticle (tLNP) delivery system. The program is positioned within the company's pipeline for the treatment of metabolic and immune disorders. The tLNP platform is designed for the targeted delivery of nucleic acids, suggesting that this program may involve the use of LNPs to deliver mRNA encoding a CAR to T cells, potentially allowing for *in vivo* CAR-T cell generation or the enhancement of *ex vivo* engineered cells. By utilizing targeted lipid nanoparticles, TLC BioSciences aims to overcome traditional delivery challenges and expand the application of CAR-T therapies beyond oncology into immunological and metabolic indications.
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD5 (T-cell surface glycoprotein CD5)CD7 (CD7 antigen)CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on tLNP CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tLNP CAR-T.